JPH09511748A - エクイリンの酸異性化によるエクイリン二重結合異性体 - Google Patents

エクイリンの酸異性化によるエクイリン二重結合異性体

Info

Publication number
JPH09511748A
JPH09511748A JP7526442A JP52644295A JPH09511748A JP H09511748 A JPH09511748 A JP H09511748A JP 7526442 A JP7526442 A JP 7526442A JP 52644295 A JP52644295 A JP 52644295A JP H09511748 A JPH09511748 A JP H09511748A
Authority
JP
Japan
Prior art keywords
bone
dehydro
isoestrone
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP7526442A
Other languages
English (en)
Japanese (ja)
Inventor
ジェミル，フレデリック・クウィンシー・ジュニア
オーゼック，チェスター・ユージーン
アデルマン，スティーブン・ジェイ
Original Assignee
アメリカン・ホーム・プロダクツ・コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アメリカン・ホーム・プロダクツ・コーポレイション filed Critical アメリカン・ホーム・プロダクツ・コーポレイション
Publication of JPH09511748A publication Critical patent/JPH09511748A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP7526442A 1994-04-08 1995-04-06 エクイリンの酸異性化によるエクイリン二重結合異性体 Withdrawn JPH09511748A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/224,849 1994-04-08
US08/224,849 US5395831A (en) 1994-04-08 1994-04-08 Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
PCT/US1995/004252 WO1995027724A1 (en) 1994-04-08 1995-04-06 An equilin double bond isomer from the acid isomerization of equilin

Publications (1)

Publication Number Publication Date
JPH09511748A true JPH09511748A (ja) 1997-11-25

Family

ID=22842497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7526442A Withdrawn JPH09511748A (ja) 1994-04-08 1995-04-06 エクイリンの酸異性化によるエクイリン二重結合異性体

Country Status (18)

Country Link
US (3) US5395831A (enExample)
EP (1) EP0754190B1 (enExample)
JP (1) JPH09511748A (enExample)
KR (1) KR970702291A (enExample)
CN (1) CN1149298A (enExample)
AT (1) ATE177111T1 (enExample)
AU (1) AU688029B2 (enExample)
CA (1) CA2186486A1 (enExample)
DE (1) DE69508068T2 (enExample)
DK (1) DK0754190T3 (enExample)
ES (1) ES2128051T3 (enExample)
GR (1) GR3030185T3 (enExample)
HU (1) HUT76338A (enExample)
IL (1) IL113178A (enExample)
NZ (1) NZ283951A (enExample)
TW (1) TW314468B (enExample)
WO (1) WO1995027724A1 (enExample)
ZA (1) ZA952771B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007254476A (ja) * 1997-06-06 2007-10-04 Schering Ag 抗酸化活性を有するエストラジオールの非エストロゲン誘導体

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395831A (en) * 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
AU7013296A (en) * 1995-08-30 1997-03-19 Eli Lilly And Company N-butylsulfonate esters of estrogens
ZA968873B (en) 1995-11-06 1997-05-28 Akzo Nobel Nv Isomerisation of equillin
US5998639A (en) * 1995-11-06 1999-12-07 Akzo Nobel, N.V. Sulfatation of estrogen mixtures
AU703814B2 (en) * 1995-12-04 1999-04-01 Wyeth Antioxidant
EP0785212A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New 19-nor-pregnene derivatives
ID18256A (id) * 1996-09-16 1998-03-19 American Home Prod Penggunaan dari 8,9-dehidro estron sebagai estrogen dengan hasil netral pada tingkat prolaktin
IL124213A (en) * 1997-05-02 2004-12-15 Akzo Nobel Nv Sulfation of estrogen mixtures
US5866561A (en) * 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
EP1330467B1 (en) 2000-11-03 2007-05-02 Washington University Modified, hydroxy-substituted aromatic structures having cytoprotective activity
US20020132802A1 (en) * 2000-11-17 2002-09-19 Washington Univeristy Cytoprotective polycyclic compounds
US20030158432A1 (en) * 2002-01-08 2003-08-21 Leonard Thomas W. Synthesis of a mixture of sulfated estrogens using a sulfur trioxide complex
US6855735B2 (en) 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
WO2003084978A1 (en) * 2002-04-01 2003-10-16 University Of Florida Steroidal quinols as prodrugs of antioxidants
US20070213310A1 (en) * 2002-04-01 2007-09-13 Laszlo Prokai Prodrugs for Use as Ophthalmic Agents
US7300926B2 (en) * 2002-04-01 2007-11-27 University Of Florida Research Foundation, Inc. Steroidal quinols and their use for estrogen replacement therapy
US7186707B2 (en) 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
US20240183014A1 (en) 2022-12-03 2024-06-06 Arthur Craig Reardon High Speed Steel Composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE205169C (enExample) *
US3394153A (en) * 1965-08-18 1968-07-23 Merck & Co Inc Process for the preparation of d, 1-8-dehydroestrone, and intermediates obtained therefrom
US3391170A (en) * 1965-09-21 1968-07-02 Smith 13-alkylogona-1, 3, 5 (10), 9 (11)-tetraenes
US3385872A (en) * 1966-08-29 1968-05-28 Syntex Corp Process for the preparation of 3-hydroxy-19-nor-delta1, 3, 5(10), 9(11)-tetraene steroids
US3471528A (en) * 1968-02-21 1969-10-07 Lilly Co Eli Method for producing delta**9(11) unsaturation in estrone and related compound
US3542819A (en) * 1968-06-11 1970-11-24 American Home Prod Process for preparing 8-isoestrone
US3649621A (en) * 1969-12-19 1972-03-14 American Home Prod Novel 3-cyclopentyl ethers of 13-alkylgon-poly-enes
US3689512A (en) * 1970-10-06 1972-09-05 American Home Prod Novel 3-etherified-1,3,5(10)-triene-steroids and process thereof
DE3014120A1 (de) * 1980-04-12 1981-10-29 Hoechst Ag, 6000 Frankfurt Verfahren zur synthese von oestron bzw. oestronderivaten
DD205169A1 (de) * 1982-05-26 1983-12-21 Adw Ddr Verfahren zur herstellung von 9(11)-dehydro-oestra-1,3,5(10)-trienen
US5210081A (en) * 1992-02-26 1993-05-11 American Home Products Corporation Alkali metal 8,9-dehydroestrone sulfate esters
US5395831A (en) * 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007254476A (ja) * 1997-06-06 2007-10-04 Schering Ag 抗酸化活性を有するエストラジオールの非エストロゲン誘導体

Also Published As

Publication number Publication date
EP0754190B1 (en) 1999-03-03
EP0754190A1 (en) 1997-01-22
HUT76338A (en) 1997-08-28
DE69508068T2 (de) 1999-10-28
US5496814A (en) 1996-03-05
WO1995027724A1 (en) 1995-10-19
ATE177111T1 (de) 1999-03-15
GR3030185T3 (en) 1999-08-31
TW314468B (enExample) 1997-09-01
IL113178A0 (en) 1995-06-29
US5395831A (en) 1995-03-07
HU9602755D0 (en) 1996-11-28
CN1149298A (zh) 1997-05-07
ES2128051T3 (es) 1999-05-01
CA2186486A1 (en) 1995-10-19
KR970702291A (ko) 1997-05-13
DE69508068D1 (de) 1999-04-08
IL113178A (en) 2000-07-26
AU688029B2 (en) 1998-03-05
DK0754190T3 (da) 1999-09-27
AU2242195A (en) 1995-10-30
NZ283951A (en) 1998-07-28
ZA952771B (en) 1996-10-04
US5552395A (en) 1996-09-03

Similar Documents

Publication Publication Date Title
JPH09511748A (ja) エクイリンの酸異性化によるエクイリン二重結合異性体
Wilder Hyperparathyroidism: tumor of the parathyroid glands associated with osteitis fibrosa
EA005592B1 (ru) Гормон-заместительная терапия
CN103957921A (zh) 18-甲基-6，7-亚甲基-3-氧代-17-孕甾-4-烯-21，17β-碳内酯、包含所述化合物的药物制剂及其在治疗子宫内膜异位症中的用途
US20060193929A1 (en) Method for treating or preventing symptoms associated with menopause
US20030191096A1 (en) Method of hormonal therapy
Larsson On the development of osteoporosis: Experimental studies in the adult rat
CN104173418A (zh) 杜仲和续断的组合物及用途
CN102266415B (zh) 一种复方中药在防治骨质疏松疾病中的应用
IE912832A1 (en) Method for treatment of bone wasting diseases
CN102961415B (zh) 忍冬木层孔菌或其提取物的用途
JPWO1994026768A1 (ja) 骨形成促進剤ならびに骨粗鬆症治療剤
JP2001048805A (ja) 骨粗鬆症、心臓血管疾患および胸部ガンを治療し予防する治療薬
Brusco et al. Osseous xanthomatosis and pathologic fractures in familial hyperlipemia (hyperglyceridemia): Observations during chlorophenoxyisobutyrate, estrogen and androgen therapy
CN1322888C (zh) 一种治疗骨质疏松的药物的用途
JP2004315454A (ja) 骨粗鬆症治療剤及び破骨細胞形成抑制剤
MacKenzie et al. Postmenopausal osteoporosis: a programme of treatment in 42 cases
Li et al. Essentiality of primary amino groups for specific activity of the lactogenic hormone
KR19990069395A (ko) 황기 추출물을 유효 성분으로 하는 골다공증 치료제
JP2531273B2 (ja) カルシウム吸収促進組成物
KR101759477B1 (ko) 스코폴린을 유효성분으로 함유하는 여성 폐경 후 골다공증 예방 또는 치료용 조성물
EP1922078A2 (en) Polypeptides useful for appetite suppression
Blum et al. Influence of oral contraceptive treatment on blood pressure and 24-hour urinary catecholamine excretion in smoking as compared with non-smoking women
JPS5917959A (ja) 酢大豆の製法とその用途
Poutasse et al. Cushing’s syndrome

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20040302